Document Detail


Performance of diadochokinetic movements in schizophrenic patients.
MedLine Citation:
PMID:  15987669     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Motor deficits are common and disabling symptoms in schizophrenic patients, which have enormous impact on the long-term outcome of the disease by affecting work performance and daily functioning. They are attributed to the disorder itself, as well as to treatment with dopamine-blocking antipsychotics. This study assessed the kinematic parameters of motor performance of a diadochokinetic hand movement in 20 drug-naïve, 20 conventionally treated (haloperidol or fluphenazine), and 20 atypically treated (olanzapine) patients, as well as in 20 healthy controls using a three-dimensional ultrasonic movement analysis system. It also tested differences in motor enhancement as induced by an attentional strategy and in dexterity advantages of motor performance for the dominant hand between the four study groups. Amplitude and peak velocity of diadochokinetic hand movements were significantly reduced in all patient groups compared to the controls, while frequency of the repetitive movement remained unaffected. The reduction was most pronounced in the conventionally treated patients. In addition, movement automation was impaired, primarily under conventional antipsychotic treatment. The study also revealed weaker effects of an attentional enhancing strategy on the movement amplitude in atypically and conventionally treated patients compared to both controls and drug-naïve patients. Alterations of dexterity could not be detected either in the drug-naïve or in the treated patients. The results indicate that patients with schizophrenia suffer from a specific primary motor deficit in diadochokinesia with reduction of amplitude and peak velocity. This deficit is significantly worsened by conventional antipsychotic treatment. Antipsychotic treatment additionally reduces the enhancing effect of an attentional strategy on motor performance.
Authors:
Albert Putzhammer; Maria Perfahl; Liane Pfeiff; Bernd Ibach; Monika Johann; Ute Zitzelsberger; Goeran Hajak
Related Documents :
11824489 - Neurodevelopmental origins of tardivelike dyskinesia in schizophrenia patients and thei...
21669119 - Dynamics of nutritional status in dying patients with acute cerebral infarction in cent...
23806729 - Contrast-enhanced ultrasonography to diagnose gallbladder perforation.
12842169 - Reduced kamin blocking in non paranoid schizophrenia: associations with schizotypy.
9104759 - Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an explorat...
9789879 - Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.
19450889 - Plaque components at coronary sites with focal spasm in patients with variant angina: v...
17681449 - Detection of second primary cutaneous melanomas.
21986769 - Bladder dysfunction and parkinsonism: current pathophysiological understanding and mana...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article     Date:  2005-06-28
Journal Detail:
Title:  Schizophrenia research     Volume:  79     ISSN:  0920-9964     ISO Abbreviation:  Schizophr. Res.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-24     Completed Date:  2006-02-14     Revised Date:  2010-09-02    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  271-80     Citation Subset:  IM    
Affiliation:
Movement Disorders Unit, Department of Psychiatry, University of Regensburg, Regensburg, Germany. albert.putzhammer@medbo.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analysis of Variance
Antipsychotic Agents / blood,  therapeutic use
Biomechanics
Case-Control Studies
Dose-Response Relationship, Drug
Dyskinesia, Drug-Induced / physiopathology*
Female
Fluphenazine / therapeutic use
Functional Laterality / physiology
Haloperidol / therapeutic use
Hand / physiopathology
Humans
Male
Movement / drug effects,  physiology
Psychiatric Status Rating Scales / statistics & numerical data
Psychomotor Disorders / drug therapy,  etiology*
Psychomotor Performance / drug effects,  physiology
Retrospective Studies
Schizophrenia / blood,  complications*,  drug therapy
Schizophrenic Psychology*
Signal Processing, Computer-Assisted
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 52-86-8/Haloperidol; 69-23-8/Fluphenazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic characterization of the mitochondrial DNA from Lepeophtheirus salmonis (Crustacea; Copepoda)...
Next Document:  The neural correlates of understanding the other's distress: a positron emission tomography investig...